Table 2 Comparison of changes in BCVA after anti-VEGF treatment compared with pretherapy changes between the two groups.

From: Elevated ApoB/A1 ratio predicts enhanced short-term efficacy of anti-VEGF therapy in diabetic macular edema

Changes in BCVA

Low ratio group

(n = 30)

High ratio group

(n = 31)

χ2

P

One month after treatment, n (%)

  

3.555

0.1874

 Decrease

7a (23.3)

2a (6.5)

  

 Stability

11a (36.7)

12a (38.7)

  

 Improvement

12a (40.0)

17a (54.8)

  

Three months after treatment, n (%)

  

7.098

0.0293

 Decrease

8a (26.7)

7a (22.6)

  

 Stability

14a (46.7)

6b (19.4)

  

 Improvement

8a (26.7)

18b (58.1)

  
  1. Post hoc two-by-two comparisons were labeled using the small letter labeling method, with different letters indicating a significant difference at the 0.05 level, 3 represent chi-square test, 4 represent Fisher’s Precision Testing. P < 0.05 was statistically significant.
Back to article page